Monitor enrollment updates and interim data readouts for the AURORA trial, which will be key catalysts. The Phase 2 OS of 25.4 months vs SOC docetaxel (9.8–11.8 months) sets a high bar; positive Phase 3 data would position aglatimagene as a first-in-class therapy in a large NSCLC segment, driving substantial upside. Candel's cash runway and potential need for financing post-Parexel engagement should also be tracked.
Price Chart
Executive Summary
Candel Therapeutics announced the initiation of a global pivotal Phase 3 AURORA trial (NCT07660094) evaluating aglatimagene besadenovec (CAN-2409) plus valacyclovir with continued pembrolizumab versus docetaxel chemotherapy in metastatic non-squamous NSCLC patients who progressed on prior pembrolizumab and platinum chemotherapy. The trial builds on Phase 2 data showing median overall survival of 25.4 months in the target population and has FDA Fast Track Designation, marking a significant pipeline catalyst.
Key Facts
- Global pivotal Phase 3 AURORA trial initiated for aglatimagene (CAN-2409) in metastatic non-squamous NSCLC.
- Primary endpoint is overall survival; secondary endpoints include safety and quality-of-life.
- Phase 2 data showed median overall survival of 25.4 months in non-squamous patients with progressive disease despite prior ICI.
- First trial site is open for enrollment; ~150 sites expected worldwide.
- Candel engaged Parexel International for global clinical operations support.
- FDA granted Fast Track Designation for aglatimagene in NSCLC.
- No financial data, revenue, or guidance disclosed in this press release.
Financial Impact
No financial figures disclosed; market cap is ~$717M. The Phase 3 initiation is a binary catalyst with significant upside if successful (potential first-in-class immunotherapy for ICI-resistant NSCLC).
Risk Factors
- Phase 3 clinical trials have a significant failure rate; the AURORA trial may not meet its primary endpoint.
- Candel is a clinical-stage biopharma with no approved products; any financing needs could dilute equity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3319644 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $10.16 | awaiting T+60 | — | $7.79 (−23.33%) |
Sep 30, 2026 26d ago | Press Release | $10.44 | awaiting T+60 | — | $7.79 (−25.38%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $7.79 (−35.94%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 3, 2026 12w ago | Press Release | $10.07 | awaiting T+60 | — | $7.79 (−22.64%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers